SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-042065
Filing Date
2023-08-14
Accepted
2023-08-14 07:53:27
Documents
76
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tals-20230630.htm   iXBRL 10-Q 3381889
2 EX-31.1 tals-ex31_1.htm EX-31.1 20031
3 EX-32.1 tals-ex32_1.htm EX-32.1 10850
  Complete submission text file 0000950170-23-042065.txt   10771552

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20230630.xsd EX-101.SCH 62570
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tals-20230630_cal.xml EX-101.CAL 42767
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20230630_pre.xml EX-101.PRE 422111
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tals-20230630_def.xml EX-101.DEF 287059
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20230630_lab.xml EX-101.LAB 519443
70 EXTRACTED XBRL INSTANCE DOCUMENT tals-20230630_htm.xml XML 1861059
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40384 | Film No.: 231166352
SIC: 2836 Biological Products, (No Diagnostic Substances)